Arovella Therapeutics Ltd (ASX:ALA) will present its iNKT cell platform and lead product ALA-101 at the prestigious annual American Association for Cancer Research (AACR) conference in April 2023.
New data to be presented
The company, which is developing the invariant Natural Killer T (iNKT) cell platform to treat cancer, will present new in vitro (test tube) and in vivo (mouse) data demonstrating how its lead candidate ALA-101 acts against patient-derived tumour cells and in aggressive leukemia models.
ALA's abstract presentation is entitled: 'Engineering allogeneic off-the-shelf CD19-directed CAR-iNKT cells without additional genetic manipulations for the treatment of hematological malignancies'.
The new data will be released at the beginning of the meeting, which will be convened from April 14 to 19 in Melbourne.
The content of the presentation will be made available online at the start of the meeting and on Arovella’s website.
Arovella’s iNKT cell platform was developed by Professor Tassos Karadimitris at Imperial College London, which is consistently ranked as one of the top 10 universities worldwide.
About Arovella Therapeutics
Arovella Therapeutics is a biotechnology company focused on developing therapies to treat human diseases. The company is developing its invariant natural killer T (iNKT) cell therapy platform with research partner Imperial College London to treat blood cancers and solid tumours.
Arovella is also expanding its DKK1-peptide targeting technology licensed from MD Anderson and used in conjunction with its iNKT cell therapy platform and commercialising ZolpiMist™, a first-in-class oral spray of zolpidem tartrate to treat short-term insomnia.
ZolpiMist is approved by the FDA and the TGA and marketed in the US. Arovella has rights to the product outside of the US and Canada.